amlodipine has been researched along with Cirrhosis in 18 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension." | 9.14 | Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 7.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| "The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis." | 7.73 | Comparative effects of pranidipine with amlodipine in rats with heart failure. ( Aizawa, Y; Gurusamy, N; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, SS; Prakash, P; Veeraveedu, PT; Wahed, MI; Watanabe, K; Wen, J, 2006) |
| "Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)." | 6.71 | Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005) |
| "To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy." | 5.16 | Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| " The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension." | 5.14 | Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009) |
| " The authors hypothesized that reduction in aldosterone production in diabetes by amlodipine or aliskiren improves diabetic kidney disease by attenuating renal oxidative stress and fibrosis." | 3.79 | Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. ( Matavelli, LC; Siragy, HM, 2013) |
| " In the present study, we evaluated the effect of an ARB, olmesartan medoxomil (CS866), on the progression of peritoneal fibrosis in peritoneal dialysis by examining its effect in a model of peritoneal fibrosis in hypertensive rats." | 3.74 | Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. ( Fukushima, R; Imai, H; Ishida, Y; Nakamoto, H; Suzuki, H; Yamanouchi, Y, 2008) |
| "The aim of the present study was to compare the cardioprotective properties of long-acting calcium channel antagonist pranidipine with amlodipine in rat model of heart failure induced by autoimmune myocarditis." | 3.73 | Comparative effects of pranidipine with amlodipine in rats with heart failure. ( Aizawa, Y; Gurusamy, N; Kamal, FA; Kodama, M; Kunisaki, M; Ma, M; Mito, S; Palaniyandi, SS; Prakash, P; Veeraveedu, PT; Wahed, MI; Watanabe, K; Wen, J, 2006) |
| " The lowest dosage of lacidipine (but not of amlodipine) restored the physiological downregulation of renin production by high salt and reduced left ventricular hypertrophy and mRNA levels of atrial natriuretic factor and transforming growth factor-beta1." | 3.71 | Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. ( Godfraind, T; Krenek, P; Kyselovic, J; Wibo, M, 2001) |
| "Thirty-nine ESRD patients with hypertension were randomly assigned to receive losartan (n=13), enalapril (n=13), or amlodipine (n=13)." | 2.71 | Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. ( Iwasaka, T; Masaki, H; Matsubara, H; Matsumoto, N; Mori, Y; Nishikawa, M; Nishiue, T; Shibasaki, Y; Tamura, K, 2005) |
| "Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta." | 1.46 | Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. ( Berg, G; Bertera, FM; Carranza, A; Chiappetta, DA; Del Mauro, JS; Donato, M; Fernandez Machulsky, N; Gelpi, RJ; González, GE; Gorzalczany, SB; Höcht, C; Morales, C; Morettón, MA; Prince, PD; Taira, CA, 2017) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| "The treatment with amlodipine reduced SBP but failed to ameliorate the ADMA-induced histological changes." | 1.34 | Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. ( Hasegawa, K; Hayashi, K; Homma, K; Itoh, H; Kimoto, M; Sugano, N; Tatematsu, S; Wakino, S; Yoshioka, K, 2007) |
| "The transgenics developed left ventricular hypertrophy along with perivascular and interstitial fibrosis which became progressively worse up to 24 weeks of age." | 1.31 | Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. ( Bishop, JE; Gohlke, P; Kiernan, LA; McEwan, JR; Montgomery, HE, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Del Mauro, JS | 1 |
| Prince, PD | 1 |
| Donato, M | 1 |
| Fernandez Machulsky, N | 1 |
| Morettón, MA | 1 |
| González, GE | 1 |
| Bertera, FM | 1 |
| Carranza, A | 1 |
| Gorzalczany, SB | 1 |
| Chiappetta, DA | 1 |
| Berg, G | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Taira, CA | 1 |
| Höcht, C | 1 |
| Nelson, JW | 1 |
| Ferdaus, MZ | 1 |
| McCormick, JA | 1 |
| Minnier, J | 1 |
| Kaul, S | 1 |
| Ellison, DH | 1 |
| Barnes, AP | 1 |
| Honma, S | 1 |
| Nakamura, K | 1 |
| Shinohara, M | 1 |
| Mitazaki, S | 1 |
| Abe, S | 1 |
| Yoshida, M | 1 |
| Nakamoto, H | 1 |
| Imai, H | 1 |
| Fukushima, R | 1 |
| Ishida, Y | 1 |
| Yamanouchi, Y | 1 |
| Suzuki, H | 1 |
| Lu, JC | 1 |
| Cui, W | 1 |
| Zhang, HL | 1 |
| Liu, F | 1 |
| Han, M | 1 |
| Liu, DM | 1 |
| Yin, HN | 1 |
| Zhang, K | 1 |
| Du, J | 2 |
| Fan, YY | 1 |
| Hitomi, H | 1 |
| Kiyomoto, H | 1 |
| Kimura, S | 1 |
| Kong, CZ | 1 |
| Noma, T | 1 |
| Kohno, M | 1 |
| Nishiyama, A | 1 |
| Nakano, D | 1 |
| Futai, R | 1 |
| Ito, T | 1 |
| Kawanishi, Y | 1 |
| Terasaki, F | 1 |
| Kitaura, Y | 1 |
| Fogari, R | 1 |
| Mugellini, A | 1 |
| Destro, M | 1 |
| Corradi, L | 1 |
| Lazzari, P | 1 |
| Zoppi, A | 1 |
| Preti, P | 1 |
| Derosa, G | 1 |
| Szabolcsi, O | 1 |
| Nagy-Toldi, A | 1 |
| Zeher, M | 1 |
| Végh, J | 1 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Shimizu, T | 1 |
| Takayama, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| Matavelli, LC | 1 |
| Siragy, HM | 1 |
| Shibasaki, Y | 2 |
| Nishiue, T | 2 |
| Masaki, H | 2 |
| Matsubara, H | 2 |
| Iwasaka, T | 2 |
| Tamura, K | 1 |
| Matsumoto, N | 1 |
| Mori, Y | 1 |
| Nishikawa, M | 1 |
| Veeraveedu, PT | 1 |
| Watanabe, K | 1 |
| Ma, M | 1 |
| Gurusamy, N | 1 |
| Palaniyandi, SS | 1 |
| Wen, J | 1 |
| Prakash, P | 1 |
| Wahed, MI | 1 |
| Kamal, FA | 1 |
| Mito, S | 1 |
| Kunisaki, M | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Hasegawa, K | 1 |
| Wakino, S | 1 |
| Tatematsu, S | 1 |
| Yoshioka, K | 1 |
| Homma, K | 1 |
| Sugano, N | 1 |
| Kimoto, M | 1 |
| Hayashi, K | 1 |
| Itoh, H | 1 |
| Dahl, K | 1 |
| Canetta, PA | 1 |
| D'Agati, VD | 1 |
| Radhakrishnan, J | 1 |
| Bishop, JE | 1 |
| Kiernan, LA | 1 |
| Montgomery, HE | 1 |
| Gohlke, P | 1 |
| McEwan, JR | 1 |
| Kyselovic, J | 1 |
| Krenek, P | 1 |
| Wibo, M | 1 |
| Godfraind, T | 1 |
4 trials available for amlodipine and Cirrhosis
| Article | Year |
|---|---|
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Pr | 2009 |
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2012 |
[Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD)].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Chan | 2002 |
Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Collagen; Double-Blind Method; Echocardiography | 2005 |
14 other studies available for amlodipine and Cirrhosis
| Article | Year |
|---|---|
Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Blood Pressure Dete | 2017 |
Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Fibrosis; Hea | 2018 |
Effect of amlodipine on mouse renal interstitial fibrosis.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Fibrosis; Kidney; Macrophages; Mice; Phosphorylation; | 2016 |
Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Dialysis Solu | 2008 |
Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiom | 2009 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia | 2009 |
[Systemic sclerosis in a patient suffering from breast cancer].
Topics: Adult; Amlodipine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Duct | 2012 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats.
Topics: Aldosterone; Amides; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cy | 2013 |
Comparative effects of pranidipine with amlodipine in rats with heart failure.
Topics: Administration, Oral; Amlodipine; Animals; Atrial Natriuretic Factor; Blood Pressure; Calcium Channe | 2006 |
Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2.
Topics: Amidohydrolases; Amlodipine; Angiotensin II; Animals; Arginine; Blood Pressure; Coronary Circulation | 2007 |
A 56-year-old woman with sarcoidosis and acute renal failure.
Topics: Acute Kidney Injury; Amlodipine; Epoetin Alfa; Erythropoietin; Female; Fibrosis; Humans; Inflammatio | 2008 |
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihy | 2000 |
Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats.
Topics: Actins; Amlodipine; Animals; Atrial Natriuretic Factor; Blood Pressure; Calcium Channel Blockers; Co | 2001 |